Fickenscher James E 4
4 · Zynerba Pharmaceuticals, Inc. · Filed Feb 9, 2023
Insider Transaction Report
Form 4
Fickenscher James E
Chief Financial Officer
Transactions
- Award
Common Stock
2023-02-07+22,547→ 362,429 total - Tax Payment
Common Stock
2023-02-08$0.60/sh−6,544$3,903→ 355,885 total
Footnotes (2)
- [F1]The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date.
- [F2]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.